The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

ABLATE is a prospective, non-randomized multi-center clinical trial to demonstrate the safety and effectiveness of the AtriCure Bipolar System for treating permanent atrial fibrillation during concomitant on-pump cardiac surgery.

Major Adverse Events consist of Death within 30 days or beyond 30 days if considered device related, Excessive Bleeding, Stroke, TIA or MI. A clinic visist was performed at 30 days to fully assess the patient for adverse events.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years and older (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Subject is greater than or equal to 18 years of age

Subject has history of permanent atrial fibrillation as defined by the ACC/AHA/ESC Guidelines

Subject is scheduled to undergo elective on-pump cardiac surgical procedure(s) for one or more of the following:

Mitral valve repair or replacement

Aortic valve repair or replacement

Tricuspid valve repair or replacement

Coronary Artery Bypass procedures

Atrial Septal Defect Repair

Patent Foramen Ovale closure

Subject's Left Ventricular Ejection Fraction ≥ 30%

Subject is able and willing to provide written informed consent and comply with study requirements